

Supplemental materials to:

Dapagliflozin and kidney outcomes in hospitalized patients with COVID-19 infection: An analysis of the DARE-19 randomized controlled trial

Heerspink HH et al.


Contents

Supplemental Figure 1: The secondary kidney outcome by pre-specified subgroups 2


Supplemental Figure 2: LS Mean eGFR (standard error) for all recorded local standard of care assessments in participants with eGFR <60 and ≥60 mL/min/1.73m² 3

Supplemental Figure 3: Histogram of the change in eGFR from baseline to Day 3 in participants with baseline eGFR <60 mL/min/1.73m² (A), and those with baseline eGFR ≥60 mL/min/1.73m² (B)..... 4

Supplemental Figure 1: The secondary kidney outcome by pre-specified subgroups



Supplemental Figure 2: LS Mean eGFR (standard error) for all recorded local standard of care assessments in participants with eGFR <60 and ≥60 mL/min/1.73m²



Supplemental Figure 3: Histogram of the change in eGFR from baseline to Day 3 in participants with baseline eGFR <60 mL/min/1.73m² (A), and those with baseline eGFR ≥60 mL/min/1.73m² (B)

